[HTML][HTML] Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
KO Alfarouk, CM Stock, S Taylor, M Walsh… - Cancer cell …, 2015 - Springer
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells
to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in …
to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in …
[HTML][HTML] Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in …
P Godoy, NJ Hewitt, U Albrecht, ME Andersen… - Archives of …, 2013 - Springer
This review encompasses the most important advances in liver functions and hepatotoxicity
and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested …
and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested …
What do drug transporters really do?
SK Nigam - Nature reviews Drug discovery, 2015 - nature.com
Potential drug–drug interactions mediated by the ATP-binding cassette (ABC) transporter
and solute carrier (SLC) transporter families are of clinical and regulatory concern. However …
and solute carrier (SLC) transporter families are of clinical and regulatory concern. However …
[HTML][HTML] Carleman estimates for semi-discrete parabolic operators and application to the controllability of semi-linear semi-discrete parabolic equations
F Boyer, J Le Rousseau - Annales de l'Institut Henri Poincare (C) Non …, 2014 - Elsevier
In arbitrary dimension, in the discrete setting of finite-differences we prove a Carleman
estimate for a semi-discrete parabolic operator, in which the large parameter is connected to …
estimate for a semi-discrete parabolic operator, in which the large parameter is connected to …
[HTML][HTML] Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components
RM Turner, M Pirmohamed - Journal of clinical medicine, 2019 - mdpi.com
Statins are a cornerstone in the pharmacological prevention of cardiovascular disease.
Although generally well tolerated, a small subset of patients experience statin-related …
Although generally well tolerated, a small subset of patients experience statin-related …
Transporters and drug-drug interactions: important determinants of drug disposition and effects
Uptake and efflux transporters determine plasma and tissue concentrations of a broad
variety of drugs. They are localized in organs such as small intestine, liver, and kidney …
variety of drugs. They are localized in organs such as small intestine, liver, and kidney …
Xenobiotic, bile acid, and cholesterol transporters: function and regulation
CD Klaassen, LM Aleksunes - Pharmacological reviews, 2010 - ASPET
Transporters influence the disposition of chemicals within the body by participating in
absorption, distribution, and elimination. Transporters of the solute carrier family (SLC) …
absorption, distribution, and elimination. Transporters of the solute carrier family (SLC) …
[HTML][HTML] Bile acid transporters
PA Dawson, T Lan, A Rao - Journal of lipid research, 2009 - ASBMB
In liver and intestine, transporters play a critical role in maintaining the enterohepatic
circulation and bile acid homeostasis. Over the past two decades, there has been significant …
circulation and bile acid homeostasis. Over the past two decades, there has been significant …
[HTML][HTML] The role of uptake and efflux transporters in the disposition of glucuronide and sulfate conjugates
E Järvinen, F Deng, W Kiander, A Sinokki… - Frontiers in …, 2022 - frontiersin.org
Glucuronidation and sulfation are the most typical phase II metabolic reactions of drugs. The
resulting glucuronide and sulfate conjugates are generally considered inactive and safe …
resulting glucuronide and sulfate conjugates are generally considered inactive and safe …
Drug interactions with lipid‐lowering drugs: mechanisms and clinical relevance
PJ Neuvonen, M Niemi… - Clinical Pharmacology & …, 2006 - Wiley Online Library
Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors
(statins), are widely used in the treatment and prevention of atherosclerotic disease. The …
(statins), are widely used in the treatment and prevention of atherosclerotic disease. The …